» Articles » PMID: 22233693

Has There Been a Change in the Natural History of Crohn's Disease? Surgical Rates and Medical Management in a Population-based Inception Cohort from Western Hungary Between 1977-2009

Abstract

Objectives: Medical therapy for Crohn's disease (CD) has changed significantly over the past 20 years with increasing use of immunosuppressives. In contrast, surgery rates are still high and there is little evidence that disease outcomes for CD have changed over the past decades. The objective of this study was to analyze the evolution of the surgical rates and medical therapy in the population-based Veszprem province database.

Methods: Data of 506 incident CD patients were analyzed (age at diagnosis: 31.5 years, s.d. 13.8 years). Both hospital and outpatient records were collected and comprehensively reviewed. The study population was divided into three groups by the year of diagnosis (cohort A: 1977-1989, cohort B: 1990-1998 and cohort C: 1999-2008).

Results: Overall, azathioprine (AZA), systemic steroid, and biological (only available after 1998) exposure was 45.8, 68.6, and 9.5%, respectively. The 1- and 5-year probability of AZA use were 3.2 and 6.2% in cohort A, 11.4 and 29.9% in cohort B, and 34.8 and 46.2% in cohort C. In a multivariate Cox-regression analysis, decade of diagnosis (P < 0.001, hazard ratio (HR)(cohorts B-C): 2.88-6.53), age at onset (P = 0.008, HR: 1.76), disease behavior at diagnosis (P < 0.001, HR(complicated): 1.76-2.07), and need for systemic steroids (P < 0.001, HR: 2.71) were significantly associated with the time to initiation of AZA therapy. Early AZA use was significantly associated with the time to intestinal surgery in CD patients; in a multivariate Cox analysis (HR: 0.43, 95% confidence interval (CI): 0.28-0.65) and after matching on propensity scores for AZA use (HR: 0.42, 95% CI: 0.26-0.67).

Conclusions: This population-based inception cohort has shown that the recent reduction in surgical rates was independently associated with increased and earlier AZA use.

Citing Articles

Impact of biologics on stoma creation and reversal in Crohn's disease: a retrospective analysis from 2007 to 2021.

Yang Y, Zhu F, Li S, Yu Z, Xu Y, Gong J Tech Coloproctol. 2025; 29(1):43.

PMID: 39775956 DOI: 10.1007/s10151-024-03085-0.


Inflammatory bowel diseases in the elderly population: epidemiology, long-term disease course, surgery rates, and biological use-data from the Veszprem county cohort between 1977 and 2020.

Angyal D, Gonczi L, Balogh F, Wetwittayakhlang P, Golovics P, Pandur T J Crohns Colitis. 2025; 19(1).

PMID: 39758021 PMC: 11772860. DOI: 10.1093/ecco-jcc/jjaf003.


Landscape of surgery in Crohn's disease across twenty years: insights from machine learning.

Zhou Z, Yu C, Liu B, Yao D, Huang Y, Wang P Transl Gastroenterol Hepatol. 2024; 9:64.

PMID: 39503021 PMC: 11535804. DOI: 10.21037/tgh-23-113.


Ten-year outcomes of a prospective population-based incidence cohort of inflammatory bowel disease patients from Canterbury, New Zealand.

Forbes A, Frampton C, Day A, DeVries M, McVicar N, Su H JGH Open. 2024; 8(10):e70038.

PMID: 39403112 PMC: 11472240. DOI: 10.1002/jgh3.70038.


Declining Trends of Reoperations and Disease Behaviour Progression in Crohn's Disease over Different Therapeutic Eras-A Prospective, Population-Based Study from Western Hungary between 1977-2020, Data from the Veszprem Cohort.

Gonczi L, Lakatos L, Golovics P, Ilias A, Pandur T, David G J Crohns Colitis. 2023; 17(12):1980-1987.

PMID: 37422727 PMC: 10798863. DOI: 10.1093/ecco-jcc/jjad117.